Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Saxenda
Pharma
Novo asks FDA to restrict compounding of legacy GLP-1 Victoza
Amid a broader campaign to snuff out compounded semaglutide, Novo Nordisk is shifting its outsourcing concerns to its legacy GLP-1 Victoza.
Fraiser Kansteiner
Jan 3, 2025 3:25pm
Novo Nordisk scolded yet again by UK drug marketing watchdog
Sep 26, 2024 10:46am
Novo weight-loss drugs pose risk of stomach problems: study
Oct 6, 2023 12:55pm
Increased demand squeezes supplies of Eli Lilly's Mounjaro—again
Jul 26, 2023 9:57am
Lawmakers, Big Pharmas push for Medicare obesity drug coverage
Jul 20, 2023 3:01pm
Weight-loss drug shortage expands to Novo's Saxenda
Jul 19, 2023 11:24am
